
Bislol2.5 mg
Opsonin Pharma Ltd.
Bisoprolol Fumarate is a cardioselective beta-1 adrenergic blocker used in the management of the following conditions: Hypertension (FDA-approved/established use): Used alone or in combination with…
Bisoprolol Fumarate is a cardioselective beta-1 adrenergic blocker used in the management of the following conditions:
Use of Bisoprolol Fumarate for any indication should be individualized and supervised by a physician.
Dosage of Bisoprolol Fumarate must be individualized by a physician according to indication and patient response. Tablets are taken orally, with or without food, generally in the morning, and should be swallowed whole with water.
| Indication | Adult Dosing |
|---|---|
| Hypertension | Initially 5 mg once daily; may be increased to 10 mg once daily and, if needed, up to a maximum of 20 mg once daily based on response. |
| Chronic stable angina | Initially 5–10 mg once daily; may be increased up to a maximum of 20 mg once daily. |
| Chronic heart failure (stable, as adjunct) | Initiated at a very low dose (e.g., 1.25 mg once daily) under close medical supervision, then doubled at intervals of at least 1–2 weeks as tolerated, up to a target/maximum of 10 mg once daily. |
Renal/hepatic impairment: In patients with severe renal impairment (creatinine clearance below approximately 40 mL/min) or significant hepatic impairment, therapy should be initiated at a lower dose (e.g., 2.5 mg once daily for hypertension) with careful titration and monitoring.
Important: Do not stop Bisoprolol Fumarate abruptly; discontinuation should be gradual (tapered over 1–2 weeks) under medical guidance, as sudden withdrawal can precipitate rebound angina, arrhythmia, or hypertension.
Side effects of Bisoprolol Fumarate are generally mild and dose-related, especially at initiation of therapy. Commonly reported effects include:
Less common but clinically important effects include hypotension, worsening of AV conduction, bronchospasm (particularly in susceptible individuals), and masking of symptoms of hypoglycemia. Patients should seek prompt medical attention for a very slow pulse, fainting, significant shortness of breath, or swelling of the legs/ankles (possible sign of worsening heart failure).
Bisoprolol Fumarate is contraindicated in patients with:
Severe bronchospastic disease (e.g., severe asthma) is generally considered a contraindication for beta-blockers as a class; although Bisoprolol Fumarate is cardioselective, this selectivity is relative and does not eliminate the risk of bronchospasm, so it should be avoided or used with extreme caution and specialist supervision in such patients.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.